This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Improving Hepatocellular Carcinoma Screening

Sponsored by Naik Vietti Violi

About this trial

Last updated 2 years ago

Study ID

CER-VD 2022-D0116

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 2 years ago

What is this trial about?

This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.

What are the participation requirements?

Yes

Inclusion Criteria

- All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations.

- Informed Consent signed by the subject

No

Exclusion Criteria

- History of HCC

- History of other malignancy

- Prior liver nodule categorized as LI-RAD 4, 5 or M

- History of liver transplantation

- Pregnancy

- MRI or MRI contrast agent precaution

- Any other condition making the patient unsuitable for the study

- Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study

Locations

Location

Status

Recruiting